retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial nejm 2023 Medscape Lilly's triple agonist, retatrutide, delivered

At the same time, if a particular formula is potentially stronger but not as well studied, research becomes less predictive, and the side effects could outweigh health benefits

This is a months-long commitment, and it works best as a layer on top of consistent training, adequate protein, decent sleep, and any hormone deficits already addressed

From GHRH to IGF-1 and downstream: clinical phenotypes and biological mechanisms

Pain Management : Studies have indicated that DSIP may have analgesic (pain-reducing) properties, possibly by interacting with opioid receptors, which could make it beneficial for chronic pain conditions